Greenwich LifeSciences Inc. announced preliminary results from the open label arm of its Phase III FLAMINGO-01 clinical trial evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences. The company reported an approximately 80% reduction in recurrence rate in the non-HLA-A*02 patient group, based on preliminary analysis using two estimation methods. This arm of the study does not have a direct placebo comparator. The data from FLAMINGO-01 is still being collected and reviewed and is considered preliminary. Previously published Phase IIb trial data showed an 80% or greater reduction in metastatic breast cancer recurrence rate over five years in HER2/neu 3+ patients treated with GLSI-100. Future updates may be provided as additional data are analyzed.